MGAT4B

Across TCGA pan-cancer cohorts, MGAT4B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MGAT4B data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MGAT4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MGAT4B expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, LUSC, and UCEC are the cancer types where MGAT4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.051	0.783	<.001	24	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	All	0.502	0.332	<.001	4	view →
HNSC	OS	Median	All	0.304	0.687	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MGAT4B–LIHC (OS)

Open the LIHC breakdown →